Pediatrix Medical Group (NYSE:MD) saw its stock surge 11.59% in pre-market trading on Monday following the release of its impressive third-quarter results and an upward revision of its full-year outlook. The healthcare services provider reported better-than-expected earnings and revenue, demonstrating resilience in a challenging healthcare environment.

The company reported third-quarter adjusted earnings of $0.67 per share, significantly surpassing the analyst consensus estimate of $0.47. This represents a 52.27% increase from the $0.44 per share reported in the same period last year. Quarterly revenue came in at $492.875 million, beating the analyst estimate of $476.493 million by 3.44%. Although this figure represents a 3.58% decrease from the previous year's $511.158 million, it still impressed investors given the current market conditions.

Pediatrix Medical's strong performance was attributed to improved collection activity, higher patient acuity, and a favorable payor mix. The company's CEO, Mark S. Ordan, highlighted these factors as key drivers of the quarter's success. Additionally, Pediatrix raised its full-year 2025 Adjusted EBITDA outlook to a range of $270 million to $290 million, up from the previous estimate of $245 million to $255 million. This upward revision further fueled investor optimism, contributing to the stock's pre-market rally.